A JAMA perspective describes an outside effort to shore up US vaccine advice

A Perspective published in JAMA on 2 September describes a privately organised effort to review the evidence behind respiratory-season vaccines and to communicate it independently of the usual federal process [s1]. It is an opinion piece by named authors, not a research paper, and it is worth reading as what it is: an account, from the people running the effort, of why they think it is needed and how it works.

What the piece says it is about

According to the journal's plain-language summary, the Perspective describes the Vaccine Integrity Project, established in 2025 in response to concerns about the stability and integrity of US vaccine policy due to disruptions to the work of the Advisory Committee on Immunization Practices (ACIP); it outlines the process for the 2026–2027 evidence review; and it summarises key findings regarding vaccine effectiveness and safety [s1].

ACIP is the federal advisory committee whose recommendations have long shaped which vaccines are advised for whom in the United States, feeding into insurance coverage and clinical practice. The Perspective's premise, as the summary frames it, is that disruption to that committee's work created a gap that an outside body set out to fill for the coming respiratory season [s1].

Who wrote it

The article's authorship is itself part of the story. The journal record lists Sandra Adamson Fryhofer and Ana Malinow Garcia of the American Medical Association in Chicago, and Michael T. Osterholm and Rochelle P. Walensky, affiliated with the Vaccine Integrity Project at the Center for Infectious Disease Research and Policy at the University of Minnesota; Walensky is also affiliated with Massachusetts General Hospital and Harvard Medical School [s1]. These are established figures in US infectious-disease policy, which is why a Perspective under their names carries weight — and also why it is not a neutral document but an argued position.

What can and cannot be taken from it

What is solid here is the existence and stated purpose of the effort: a named group, formed in 2025, publishing a described process for reviewing 2026–2027 respiratory-season vaccines and putting its reasoning in a major medical journal [s1]. That is a concrete development in how vaccine guidance is being produced and communicated this year.

What this summary does not let a reader do is independently check the review's conclusions. The Perspective is said to summarise key findings on vaccine effectiveness and safety [s1], but a Perspective is a venue for expert argument, and the underlying evidence reviews are where the specific effectiveness and safety numbers would live. A parallel, non-governmental review also raises its own questions — about methods, transparency and how its recommendations sit alongside or against official guidance — that only the full documentation can answer.

The context that makes this notable

To see why a Perspective like this appears now, it helps to know what ACIP normally does. Its recommendations have historically set the default answer to "who should get which vaccine," and those recommendations flow downstream into what insurers cover and what clinicians offer. When that channel functions, there is little reason for senior figures to stand up a parallel review; the appearance of one is a signal about the channel, not just about vaccines. The summary attributes the project's founding directly to concerns about the stability and integrity of US vaccine policy arising from disruptions to ACIP's work [s1].

It is worth being precise about what this article can and cannot verify. That the Vaccine Integrity Project exists, was formed in 2025, and has published a described process in JAMA is on the record [s1]. The characterisation of ACIP as "disrupted," and the judgement that an alternative review is warranted, are the authors' framing — a reasoned position from experienced people, but a position, and one that others involved in vaccine policy might describe differently. Readers should weigh it as argument backed by named, credible authors rather than as a neutral finding of fact.

Why it matters

Vaccine recommendations only work if clinicians, insurers and the public treat them as trustworthy. When the standard federal channel is described by senior figures as disrupted, the appearance of an alternative review is significant regardless of what it concludes: it signals that some of the field no longer assumes the usual process will deliver timely, credible guidance for the season ahead. It also introduces the possibility of competing recommendations, which is precisely the fragmentation the project's own title — "Restoring Confidence and Trust" — says it wants to avoid [s1].

For readers, the practical takeaway is narrow: this is one expert group's stated approach to the 2026–2027 respiratory-vaccine season, published as a Perspective. Decisions about individual vaccination remain a matter for a person and their clinician, and this article does not offer medical advice.

Sources

• Respiratory Season Virus Vaccines: Restoring Confidence and Trust, JAMA, 2 September 2026